| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| K Sugi, N Itaya, T Katsura, M Igi, S Yamazaki, T Ishibashi, T Yamaoka, Y Kawada, Y Tagami, M Otsuki, T Ohshim. Improved synthesis of paroxetine hydrochloride propan-2-ol solvate through one of metabolites in humans, and characterization of the solvate crystals. Chemical & pharmaceutical bulletin. vol 48. issue 4. 2000-07-13. PMID:10783073. |
paroxetine, a potent and selective inhibitor of 5-hydroxytryptamine (serotonin) uptake, was prepared through a piperidine derivative, which was reported to be one of the paroxetine metabolites in humans. |
2000-07-13 |
2023-08-12 |
Not clear |
| S Morinobu, D S Russel, S Sugawara, M Takahashi, K Fujimak. Regulation of phosphorylation of cyclic AMP response element-binding protein by paroxetine treatments. Clinical neuropharmacology. vol 23. issue 2. 2000-07-12. PMID:10803801. |
the present study was undertaken to examine the effect of paroxetine, a selective serotonin reuptake inhibitor, on the phosphorylation of cyclic adenosine monophosphate (camp) response element binding protein (creb) in the rat brain. |
2000-07-12 |
2023-08-12 |
rat |
| S Morinobu, D S Russel, S Sugawara, M Takahashi, K Fujimak. Regulation of phosphorylation of cyclic AMP response element-binding protein by paroxetine treatments. Clinical neuropharmacology. vol 23. issue 2. 2000-07-12. PMID:10803801. |
these findings suggest that the enhancement of intracellular signal transduction after the activation of serotonin receptors may be attenuated after chronic paroxetine treatment, and this attenuation may be, at least in part, involved in the therapeutic efficacy of paroxetine. |
2000-07-12 |
2023-08-12 |
rat |
| K E Goeringer, L Raymon, G D Christian, B K Loga. Postmortem forensic toxicology of selective serotonin reuptake inhibitors: a review of pharmacology and report of 168 cases. Journal of forensic sciences. vol 45. issue 3. 2000-07-07. PMID:10855970. |
the four selective serotonin reuptake inhibitors (ssris) considered--fluoxetine, fluvoxamine, sertraline and paroxetine--can result in toxicity and death through contributing to serotonergic excess resulting in serotonin syndrome, inhibiting the metabolism of other centrally acting drugs, leading to accumulation of toxic concentrations, and exerting complex vasoactive effects on the vascular smooth muscle. |
2000-07-07 |
2023-08-12 |
Not clear |
| B G Pollock, F Laghrissi-Thode, W R Wagne. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of clinical psychopharmacology. vol 20. issue 2. 2000-06-28. PMID:10770450. |
therefore, platelet activation in depressed patients with ihd seems to be inhibited by the selective serotonin reuptake inhibitor paroxetine. |
2000-06-28 |
2023-08-12 |
human |
| B B Rasmussen, K Brøse. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Therapeutic drug monitoring. vol 22. issue 2. 2000-06-08. PMID:10774624. |
the selective serotonin reuptake inhibitors (ssris) comprise citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline and they differ from each other in chemical structure, by pharmacokinetic properties and, most importantly, with respect to enzyme-specific metabolism and interactions. |
2000-06-08 |
2023-08-12 |
Not clear |
| R Schlösser, H Wetzel, H Dörr, W Rossbach, C Hiemke, O Benker. Effects of subchronic paroxetine administration on night-time endocrinological profiles in healthy male volunteers. Psychoneuroendocrinology. vol 25. issue 4. 2000-05-31. PMID:10725614. |
to evaluate the subchronic effects of paroxetine, a selective serotonin reuptake inhibitor, on nocturnal endocrinological profiles, eight healthy male volunteers with no personal or family history of a psychiatric or neurological disease were administered paroxetine (30 mg/day) or placebo in a double-blind cross-over design. |
2000-05-31 |
2023-08-12 |
human |
| C Vilpoux, I Leroux-Nicollet, L Naudon, R Raisman-Vozari, J Costenti. Reserpine or chronic paroxetine treatments do not modify the vesicular monoamine transporter 2 expression in serotonin-containing regions of the rat brain. Neuropharmacology. vol 39. issue 6. 2000-05-25. PMID:10727718. |
the expression of the vesicular monoamine transporter 2 (vmat2) has been studied in the serotonergic system of the rat brain after an 18 day treatment with the serotonin selective-reuptake inhibitor paroxetine (10 mg/kg, i.p., once daily). |
2000-05-25 |
2023-08-12 |
rat |
| C Vilpoux, I Leroux-Nicollet, L Naudon, R Raisman-Vozari, J Costenti. Reserpine or chronic paroxetine treatments do not modify the vesicular monoamine transporter 2 expression in serotonin-containing regions of the rat brain. Neuropharmacology. vol 39. issue 6. 2000-05-25. PMID:10727718. |
it is concluded that neither a reduction (reserpine) nor an enhancement (paroxetine) of the serotonin transmission induces vmat2 regulation in serotonergic system in the rat brain. |
2000-05-25 |
2023-08-12 |
rat |
| K L Weihs, E C Settle, S R Batey, T L Houser, R M Donahue, J A Asche. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. The Journal of clinical psychiatry. vol 61. issue 3. 2000-05-25. PMID:10817105. |
this study compared the efficacy and safety of bupropion sustained release (sr) with the selective serotonin reuptake inhibitor paroxetine in the treatment of major depression in elderly outpatients. |
2000-05-25 |
2023-08-12 |
Not clear |
| C R McKittrick, A M Magariños, D C Blanchard, R J Blanchard, B S McEwen, R R Saka. Chronic social stress reduces dendritic arbors in CA3 of hippocampus and decreases binding to serotonin transporter sites. Synapse (New York, N.Y.). vol 36. issue 2. 2000-05-12. PMID:10767055. |
[(3)h]paroxetine binding to the 5htt was decreased in ammon's horn in both dominants and subordinates compared to controls, while 5htt binding remained unchanged in dentate gyrus and raphe. |
2000-05-12 |
2023-08-12 |
rat |
| C M Helgason, J L Frank, D R Johnson, M G Frank, S E Hendrick. The effects of St. John's Wort (Hypericum perforatum) on NK cell activity in vitro. Immunopharmacology. vol 46. issue 3. 2000-05-11. PMID:10741904. |
however, in corroboration of previous studies, 5-ht, the selective serotonin reuptake inhibitors (ssris), paroxetine and norfluoxetine, and alpha-interferon augmented nkca above control levels. |
2000-05-11 |
2023-08-12 |
Not clear |
| M J Duncan, C J Crafton, D L Wheele. Aging regulates 5-HT(1B) receptors and serotonin reuptake sites in the SCN. Brain research. vol 856. issue 1-2. 2000-05-10. PMID:10677628. |
quantitative autoradiography was conducted using [125i]iodocyanopindolol ([125i]icyp) and [3h]paroxetine, selective radioligands for the 5-ht(1b) receptors and the serotonin reuptake sites, respectively. |
2000-05-10 |
2023-08-12 |
Not clear |
| N Haddjeri, S T Szabo, C de Montigny, P Blie. Increased tonic activation of rat forebrain 5-HT(1A) receptors by lithium addition to antidepressant treatments. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 22. issue 4. 2000-05-01. PMID:10700654. |
when the tricyclic antidepressant imipramine (10 mg/kg/day, sc), the monoamine oxidase inhibitor tranylcypromine (2.5 mg/kg/day, sc) and the selective 5-ht reuptake inhibitor paroxetine (10 mg/kg/day, sc) were administered alone for 21 days, a dose of 50 microg/kg of way 100635 was needed to increase significantly the firing activity of these neurons. |
2000-05-01 |
2023-08-12 |
rat |
| L O Cavallazzi, A K Grezesiu. [Serotonin syndrome associated to the use of paroxetine. Case report]. Arquivos de neuro-psiquiatria. vol 57. issue 3B. 2000-04-20. PMID:10751931. |
[serotonin syndrome associated to the use of paroxetine. |
2000-04-20 |
2023-08-12 |
Not clear |
| L O Cavallazzi, A K Grezesiu. [Serotonin syndrome associated to the use of paroxetine. Case report]. Arquivos de neuro-psiquiatria. vol 57. issue 3B. 2000-04-20. PMID:10751931. |
we report on a case of serotonin syndrome associated to the use of the paroxetine, a serotonin reuptake inhibitor drug. |
2000-04-20 |
2023-08-12 |
Not clear |
| G H Moll, C Mehnert, M Wicker, N Bock, A Rothenberger, E Rüther, G Huethe. Age-associated changes in the densities of presynaptic monoamine transporters in different regions of the rat brain from early juvenile life to late adulthood. Brain research. Developmental brain research. vol 119. issue 2. 2000-04-11. PMID:10675775. |
the binding parameters of highly selective ligands of serotonin (5-ht) transporters ([3h]paroxetine), noradrenaline (ne) transporters ([3h]nisoxetine), and of dopamine (da) transporters ([3h]gbr-12935) were determined on membrane preparations from frontal cortex, striatum, midbrain and brain stem of wistar rats on postnatal days 25, 50, 90 and 240, i.e., from the time of weaning till late adulthood. |
2000-04-11 |
2023-08-12 |
rat |
| D W Carley, M Radulovack. Mirtazapine, a mixed-profile serotonin agonist/antagonist, suppresses sleep apnea in the rat. American journal of respiratory and critical care medicine. vol 160. issue 6. 2000-04-03. PMID:10588592. |
serotonin enhancing drugs, including l-tryptophan and, more recently, fluoxetine and paroxetine, have been tested as pharmacologic treatments for sleep apnea syndrome. |
2000-04-03 |
2023-08-12 |
rat |
| D Marazziti, L Dell'Osso, S Presta, C Pfanner, A Rossi, I Masala, S Baroni, G Giannaccini, A Lucacchini, G B Cassan. Platelet [3H]paroxetine binding in patients with OCD-related disorders. Psychiatry research. vol 89. issue 3. 2000-03-31. PMID:10708268. |
we therefore compared the binding of [3h]paroxetine ([3h]par), a ligand that specifically labels the serotonin (5-ht) transporter, in platelets of drug-free outpatients suffering from various ocd-related disorders with binding in platelets of ocd patients and healthy subjects. |
2000-03-31 |
2023-08-12 |
human |
| K Maguire, T Norman, G Burrows, M Hopwood, P Morri. Platelet paroxetine binding in post-traumatic stress disorder. Psychiatry research. vol 77. issue 1. 2000-03-31. PMID:10710169. |
sixty-two subjects, 45 with post-traumatic stress disorder (ptsd) and 17 healthy control subjects, were examined in a study of serotonin function measured by [3h]paroxetine binding to platelet membranes. |
2000-03-31 |
2023-08-12 |
human |